Antti S. Rannikko

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 144 publications

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Journal: The Journal of urology

Published: July 09, 2026

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Journal: Future oncology (London, England)

Published: July 06, 2026

Why Look Further When the Solution Is in Front of You - or Is It? The Value of Confirmatory PSA in Prostate Cancer Screening.

Why Look Further When the Solution Is in Front of You - or Is It? The Value of Confirmatory PSA in Prostate Cancer Screening.

Journal: European urology

Published: July 06, 2026

Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer.

Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer.

Journal: European urology focus

Published: April 02, 2026

ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy.

ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy.

Journal: European urology

Published: March 25, 2026

ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy.

ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy.

Journal: European urology

Published: March 25, 2026

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: February 06, 2026

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: February 06, 2026

Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.

Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.

Journal: BJU international

Published: December 15, 2025

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.

Journal: The Journal of urology

Published: December 09, 2025

Novel therapeutic strategies for ccRCC through integration of systemic drug combinations and oncolytic adenovirus immunotherapy.

Novel therapeutic strategies for ccRCC through integration of systemic drug combinations and oncolytic adenovirus immunotherapy.

Journal: Frontiers in immunology

Published: December 04, 2025

PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three Centers.

PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three Centers.

Journal: European urology oncology

Published: November 26, 2025

Showing 1-12 of 144

Last Updated: 09/26/2026